We isolate B. pseudolongum from mouse or human fecal samples under strict anaerobiosis (validated redox control). Primary and secondary screens quantify acid/bile tolerance, growth kinetics, acetate/lactate output, and SCFA fingerprints. Phenotypic triage selects B. pseudolongum candidates that align with your target attributes for downstream MoA, colonization, and formulation research.
Accurate species confirmation of B. pseudolongum is delivered via 16S rRNA profiling plus whole-genome sequencing for strain typing, phylogenomics, and provenance tracking. We compile GLP-style ID dossiers—ANI/AAI, MLST, BSH gene presence, glycan-use loci—and a traceable lineage report to support exclusivity statements and long-term bio-banking strategies.
We construct modular, assay-ready panels to profile B. pseudolongum: acetate and lactate production, bile salt deconjugation, tryptophan-to-indole conversion, and inosine secretion. Readouts include epithelial barrier markers, NF-κB/AHR reporter signals, and cytokine panels, enabling pathway-level attribution and selection of strains with consistent, quantifiable MoA signatures.
In epithelial, organoid, and macrophage co-cultures, we benchmark B. pseudolongum adhesion, TEER, tight-junction proteins (ZO-1/occludin/claudins), and context-dependent signaling (e.g., AHR, GPR43). Optional modules quantify inosine-responsive T-cell activation under defined co-stimulation to map host pathways relevant to your hypothesis and species-specific endpoints.
We optimize anaerobic fermentation for B. pseudolongum using DoE across medium composition, pH control, ORP, feed strategies, and gas overlays. Deliverables include scale-up recipes from shake flask to benchtop bioreactor, mass-balance/CFU yield curves, and metabolite profiles to ensure robust growth and reproducibility for downstream formulation studies.
Creative Biolabs executes research-grade, anaerobic scale-up runs (1–10 L, custom on request) for B. pseudolongum. Batches ship with SOPs, batch records, CoAs (CFU, purity, moisture, endotoxin where applicable), and comparative SCFA/metabolite spectra. Output supports stability testing, delivery-vehicle screening, and in vivo dosing design in preclinical programs.
We rationally stabilize B. pseudolongum with cryo/lyoprotectant matrices (e.g., disaccharides, amino acids, proteins), controlled freezing/primary-drying ramps, and residual-moisture targets. When indicated, we evaluate microencapsulation to enhance gastric survival and shelf-life, reporting viability decay kinetics (isothermal/accelerated) and package-oxygen sensitivity for your distribution scenarios.
We design B. pseudolongum research formulations (powder, capsule, suspension) with excipient systems matched to the intended use and handling constraints. You receive oxygen-/water-activity guidance, container/closure recommendations, and provisional release criteria (e.g., CFU, purity, water activity) aligned to your study design and downstream logistics.
Fig.1 Gram staining of B. pseudolongum.
